Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Immunofluorescence (IF)
Purification
SODD Antibody is Antibody is DEAE purified.
Immunogen
SODD antibody was raised against a peptide corresponding to amino acids near the amino terminus of human SODD. The immunogen is located within the first 50 amino acids of SODD.
BAG4
Reactivity: Human, Mouse, Rat, Cow, Dog, Horse, Monkey, Bat
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
SODD antibody can be used for detection of SODD by Western blot at 0.5 μ,g/mL. An approximately 60 kDa band can be detected. Antibody can also be used for immunocytochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
SODD Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
SODD antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
SODD Antibody: Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNF-R1 and Fas. Several novel death receptors including DR3, DR4, DR5, and DR6 were recently identified. Cell death signal is transduced by death domain containing adapter molecules through the interaction with death domain of these death receptors. A novel TNF-R1 interacting protein was recently identified and designated SODD for silencer of death domains. SODD associates with the death domain of TNF-R1 and prevents constitutive activation of TNF-R1 signaling. TNF treatment releases SODD and permits adapter molecules such as TRADD recruiting to the active TNF-R1 complex, which activates TNF signaling pathways. SODD also interacts with DR3. SODD is ubiquitously expressed in human tissues and cell lines.